{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T12:17:20Z","timestamp":1775218640846,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T00:00:00Z","timestamp":1601596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T00:00:00Z","timestamp":1601596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s12020-020-02506-y","type":"journal-article","created":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T08:03:48Z","timestamp":1601625828000},"page":"344-350","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Effectiveness and safety of lomitapide in a patient with familial chylomicronemia syndrome"],"prefix":"10.1007","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1259-8284","authenticated-orcid":false,"given":"Angelo B.","family":"Cefal\u00f9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonina","family":"Giammanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Noto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossella","family":"Spina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Cabibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo M.","family":"Barbagallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Averna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,2]]},"reference":[{"key":"2506_CR1","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","volume":"2","author":"RA Hegele","year":"2014","unstructured":"R.A. Hegele, H.N. Ginsberg, M.J. Chapman, B.G. Nordestgaard, J.A. Kuivenhoven, M. Averna, J. Bor\u00e9n, E. Bruckert, A.L. Catapano, O.S. Descamps et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2, 655\u2013662 (2014)","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"2506_CR2","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nrendo.2015.26","volume":"11","author":"AJ Brahm","year":"2015","unstructured":"A.J. Brahm, R.A. Hegele, Chylomicronaemia-current diagnosis and future therapies. Nat. Rev. Endocrinol. 11(6), 352\u2013362 (2015)","journal-title":"Nat. Rev. Endocrinol."},{"issue":"4","key":"2506_CR3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.pan.2016.02.011","volume":"16","author":"RA Carr","year":"2016","unstructured":"R.A. Carr, B.J. Rejowski, G.A. Cote, H.A. Pitt, N.J. Zyromski, Systematic review of hypertriglyceridemia-induced acute pancreatitis: a more virulent etiology? Pancreatology 16(4), 469\u2013476 (2016)","journal-title":"Pancreatology"},{"issue":"4","key":"2506_CR4","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/ajg.2009.27","volume":"104","author":"W Tsuang","year":"2009","unstructured":"W. Tsuang, U. Navaneethan, L. Ruiz, J.B. Palascak, A. Gelrud, Hypertriglyceridemic pancreatitis: presentation and management. Am. J. Gastroenterol. 104(4), 984\u2013991 (2009)","journal-title":"Am. J. Gastroenterol."},{"issue":"1","key":"2506_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.atherosclerosis.2015.04.815","volume":"241","author":"C Rabacchi","year":"2015","unstructured":"C. Rabacchi, L. Pisciotta, A.B. Cefal\u00f9, D. Noto, R. Fresa, P. Tarugi, M. Averna, S. Bertolini, S. Calandra, Spectrum of mutations of the LPL gene identified in Italy in patients with severe hypertriglyceridemia. Atherosclerosis 241(1), 79\u201386 (2015)","journal-title":"Atherosclerosis"},{"issue":"1","key":"2506_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jacl.2015.09.007","volume":"10","author":"MJ Ariza","year":"2016","unstructured":"M.J. Ariza, P.L. Mart\u00ednez-Hern\u00e1ndez, D. Ibarretxe, C. Rabacchi, J. Rioja, C. Grande-Arag\u00f3n, N. Plana, P. Tarugi, G. Olivecrona et al. Novel mutations in the GPIHBP1 gene identified in 2 patients with recurrent acute pancreatitis. J. Clin. Lipidol. 10(1), 92\u2013100.e1 (2016)","journal-title":"J. Clin. Lipidol."},{"issue":"2","key":"2506_CR7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1161\/01.ATV.0000153087.36428.dd","volume":"25","author":"C Priore Oliva","year":"2005","unstructured":"C. Priore Oliva, L. Pisciotta, G. Li Volti, M.P. Sambataro, A. Cantafora, A. Bellocchio, A. Catapano, P. Tarugi, S. Bertolini, S. Calandra, Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol. 25(2), 411\u2013417 (2005)","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"2506_CR8","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.jacl.2017.01.003","volume":"11","author":"AB Cefal\u00f9","year":"2017","unstructured":"A.B. Cefal\u00f9, R. Spina, D. Noto, V. Ingrassia, V. Valenti, A. Giammanco, F. Fayer, G. Misiano, G. Cocorullo, C. Scrimali et al. Identification of a novel LMF1 nonsense mutation responsible for severe hypertriglyceridemia by targeted next-generation sequencing. J. Clin. Lipidol. 11(1), 272\u2013281.e8 (2017)","journal-title":"J. Clin. Lipidol."},{"key":"2506_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1365-2796.2012.02516.x","volume":"272","author":"RP Surendran","year":"2012","unstructured":"R.P. Surendran, M.E. Visser, S. Heemelaar, J. Wang, J. Peter, J.C. Defesche, J.A. Kuivenhoven, M. Hosseini, M. P\u00e9terfy, J.J. Kastelein et al. Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia. J. Intern. Med. 272, 185\u2013196 (2012)","journal-title":"J. Intern. Med."},{"issue":"1","key":"2506_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ajhg.2011.11.028","volume":"90","author":"L Basel-Vanagaite","year":"2012","unstructured":"L. Basel-Vanagaite, N. Zevit, A. Har Zahav, L. Guo, S. Parathath, M. Pasmanik-Chor, A.D. McIntyre, J. Wang, A. Albin-Kaplanski, C. Hartman et al. Transient infantile hypertriglyceridemia, fatty liver, and hepatic fibrosis caused by mutated GPD1, encoding glycerol-3-phosphate dehydrogenase 1. Am. J. Hum. Genet. 90(1), 49\u201360 (2012)","journal-title":"Am. J. Hum. Genet."},{"issue":"4","key":"2506_CR11","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.jacl.2018.03.093","volume":"12","author":"RA Hegele","year":"2018","unstructured":"R.A. Hegele, A.J. Berberich, M.R. Ban, J. Wang, A. Digenio, V.J. Alexander, L. D\u2019Erasmo, M. Arca, A. Jones, E. Bruckert et al. Clinical and biochemical features of different molecular etiologies of familial chylomicronemia. J. Clin. Lipidol. 12(4), 920\u2013927.e4 (2018)","journal-title":"J. Clin. Lipidol."},{"issue":"2","key":"2506_CR12","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jacl.2018.03.032","volume":"12","author":"A Gelrud","year":"2018","unstructured":"A. Gelrud, A. Digenio, V. Alexander, K. Williams, A. Hsieh, I. Gouni-Berthold, E. Bruckert, E. Stroes, R. Geary, S. Hughes et al. Treatment with volanesorsen (VLN) reduced triglycerides and pancreatitis in patients with FCS and sHTG vs placebo: results of the APPROACH and COMPASS. J. Clin. Lipidol. 12(2), 537 (2018)","journal-title":"J. Clin. Lipidol."},{"key":"2506_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1089\/nat.2016.0650","volume":"27","author":"ST Crooke","year":"2017","unstructured":"S.T. Crooke, B.F. Baker, J.L. Witztum, T.J. Kwoh, N.C. Pham, N. Salgado, B.W. McEvoy, W. Cheng, S.G. Hughes, S. Bhanot et al. The effects of 2\u2019-O-methoxyethyl containing antisense oligonucleotides on platelets in human clinical trials. Nucleic Acid Ther. 27, 121\u2013129 (2017)","journal-title":"Nucleic Acid Ther."},{"key":"2506_CR14","doi-asserted-by":"publisher","first-page":"A1724","DOI":"10.1016\/S0735-1097(18)32265-4","volume":"71","author":"VJ Alexander","year":"2018","unstructured":"V.J. Alexander, A. Digenio, S. Xia, E. Hurh, S. Hughes, R.S. Geary, J.L. Witztum, S. Tsimikas, Inhibition of apolipoprotein C-III with GalNac conjugated antisense drug potently lowes fasting serum apolipoprotein C-III and triglyceride levels in healthy volunteers with elevated triglycerides. J. Am. Coll. Cardiol. 71, A1724 (2018)","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"2506_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1612790","volume":"377","author":"FE Dewey","year":"2017","unstructured":"F.E. Dewey, V. Gusarova, R.L. Dunbar, C. O\u2019Dushlaine, C. Schurmann, O. Gottesman, S. McCarthy, C.V. Van Hout, S. Bruse, H.M. Dansky et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N. Engl. J. Med. 377(3), 211\u2013221 (2017)","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"2506_CR16","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMoa1701329","volume":"377","author":"MJ Graham","year":"2017","unstructured":"M.J. Graham, R.G. Lee, T.A. Brandt, L.J. Tai, W. Fu, R. Peralta, R. Yu, E. Hurh, E. Paz, B.W. McEvoy et al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N. Engl. J. Med. 377(3), 222\u2013232 (2017)","journal-title":"N. Engl. J. Med."},{"key":"2506_CR17","doi-asserted-by":"crossref","unstructured":"D. Gaudet, E. Karwatowska-Prokopczuk, S.J. Baum, E. Hurh, J. Kingsbury, V.J. Bartlett, A.L. Figueroa, P. Piscitelli, W. Singleton, J.L. Witztum, et al. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. Eur. Heart J. ehaa689 (2020). Online ahead of print","DOI":"10.1093\/eurheartj\/ehaa689"},{"issue":"23","key":"2506_CR18","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.2174\/0929867326666190121120735","volume":"27","author":"A Giammanco","year":"2020","unstructured":"A. Giammanco, A.B. Cefal\u00f9, D. Noto, M.R. Averna, Therapeutic options for homozygous familial hypercholesterolemia: the role of Lomitapide. Curr. Med. Chem. 27(23), 3773\u20133783 (2020)","journal-title":"Curr. Med. Chem."},{"issue":"3","key":"2506_CR19","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1001\/jamainternmed.2013.13309","volume":"174","author":"FM Sacks","year":"2014","unstructured":"F.M. Sacks, M. Stanesa, R.A. Hegele, Severe hypertriglyceridemia with pancreatitis: thirteen years\u2019 treatment with Lomitapide. JAMA Intern. Med. 174(3), 443\u2013447 (2014)","journal-title":"JAMA Intern. Med."},{"issue":"12","key":"2506_CR20","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1080\/13543784.2016.1254187","volume":"25","author":"AJ Brahm","year":"2016","unstructured":"A.J. Brahm, R.A. Hegele, Lomitapide for the treatment of hypertriglyceridemia. Expert Opin. Investig. Drugs 25(12), 1457\u20131463 (2016)","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"3","key":"2506_CR21","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/trf.13400","volume":"56","author":"D Di Bona","year":"2016","unstructured":"D. Di Bona, A.B. Cefal\u00f9, E. Scir\u00e8, G.M. Lima, C.M. Rizzo, A. Giammanco, C.M. Barbagallo, M.R. Averna, S. Rizzo, C. Caruso, Albumin versus solvent\/detergent-treated pooled plasma as replacement fluid for long-term plasma exchange therapy in a patient with primary hypertriglyceridemia and recurrent hyperlipidemic pancreatitis. Transfusion 56(3), 755\u2013760 (2016)","journal-title":"Transfusion"},{"key":"2506_CR22","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"P Angulo","year":"2007","unstructured":"P. Angulo, J.M. Hui, G. Marchesini et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45, 846\u2013854 (2007)","journal-title":"Hepatology"},{"issue":"5","key":"2506_CR23","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1148\/rg.295085186","volume":"29","author":"X Ma","year":"2009","unstructured":"X. Ma, N.S. Holalkere, R.A. Kambadakone, M. Mino-Kenudson, P.F. Hahn, D.V. Sahani, Imaging-based quantification of hepatic fat: methods and clinical applications. Radiographics 29(5), 1253\u20131277 (2009)","journal-title":"Radiographics"},{"issue":"6","key":"2506_CR24","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"D.E. Kleiner, E.M. Brunt, M. Van Natta, C. Behling, M.J. Contos, O.W. Cummings, L.D. Ferrell, Y.C. Liu, M.S. Torbenson, A. Unalp-Arida, Nonalcoholic Steatohepatitis Clinical Research Network et al., Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41(6), 1313\u20131321 (2005)","journal-title":"Hepatology"},{"issue":"11","key":"2506_CR25","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1080\/14779072.2017.1372193","volume":"15","author":"A Gelrud","year":"2017","unstructured":"A. Gelrud, K.R. Williams, A. Hsieh, A.R. Gwosdow, A. Gilstrap, A. Brown, The burden of familial chylomicronemia syndrome from the patients\u2019 perspective. Expert Rev. Cardiovasc. Ther. 15(11), 879\u2013887 (2017)","journal-title":"Expert Rev. Cardiovasc. Ther."},{"issue":"3","key":"2506_CR26","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1161\/CIRCULATIONAHA.117.028208","volume":"136","author":"DJ Blom","year":"2017","unstructured":"D.J. Blom, M.R. Averna, E.A. Meagher, H. du Toit Theron, C.R. Sirtori, R.A. Hegele, P.K. Shah, D. Gaudet, C. Stefanutti, G.B. Vigna et al. Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in patients with homozygous familial hypercholesterolemia. Circulation 136(3), 332\u2013335 (2017)","journal-title":"Circulation"},{"issue":"4","key":"2506_CR27","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/hep.27844","volume":"62","author":"S Petta","year":"2015","unstructured":"S. Petta, M. Maida, F.S. Macaluso, V. Di Marco, C. Camm\u00e0, D. Cabibi, A. Crax\u00ec, The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. Hepatology 62(4), 1101\u20131110 (2015)","journal-title":"Hepatology"},{"issue":"5","key":"2506_CR28","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1111\/liv.12584","volume":"35","author":"S Petta","year":"2015","unstructured":"S. Petta, E. Vanni, E. Bugianesi, V. Di Marco, C. Camm\u00e0, D. Cabibi, L. Mezzabotta, A. Crax\u00ec, The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver Int. 35(5), 1566\u20131573 (2015)","journal-title":"Liver Int."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-020-02506-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-020-02506-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-020-02506-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T01:02:42Z","timestamp":1633136562000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-020-02506-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["2506"],"URL":"https:\/\/doi.org\/10.1007\/s12020-020-02506-y","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,2]]},"assertion":[{"value":"17 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"ABC: has been speaker for Sanofi, Merck, and Amryt Pharmaceuticals. AG: nothing to disclose. DN: has been speaker for Sanofi, Merck, and Amgen. RS: nothing to disclose. DC: nothing to disclose. CMB: has been speaker for Sanofi, Merck, and Amgen. MA: has been consultant and speaker for Amgen, Sanofi, Merck, ISIS, Genzyme, and Amryt Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}